Design, synthesis, anti-tubercular activity, and computational studies of novel 3-(quinolin-3-yl)-1-phenylprop-2-en-1-one derivatives

被引:0
作者
Bhanwala, Neeru [1 ]
Sundaramoorthy, Niranjana Sri [2 ]
Gollapudi, Sirisha [1 ]
Sharma, Anita [1 ]
Singh, Ramandeep [2 ]
Khatik, Gopal L. [1 ]
机构
[1] Natl Inst Pharmaceut Educ & Res Raebareli, Dept Med Chem, Transit Campus, Lucknow, Uttar Pradesh, India
[2] Translat Hlth Sci & Technol Inst, Ctr TB Res, TB Res Lab, Faridabad, Haryana, India
关键词
Quinoline; Synthesis; Anti-tubercular; Mycobacterium tuberculosis; In; -silico; H(37)Rv strain; ATP SYNTHASE; QUINOLINE DERIVATIVES; DRUG; BEDAQUILINE; RESISTANCE; OXADIAZOLE;
D O I
10.1007/s00044-024-03295-z
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Tuberculosis (TB) is a contagious disease caused by M. tuberculosis (Mtb) affecting people across the globe. Quinoline and chalcone cores have good anti-tubercular properties; thus, we have designed a hybrid scaffold containing quinoline and chalcone. A series of 3-(quinolin-3-yl)-1-phenylprop-2-en-1-one analogs 7a-p and 8a-k were synthesized through different reactions involving nucleophilic substitution, Vilsmeier Haack formylation, Claisen Schmidt condensation, and demethylation. Spectroscopic methods, including H-1 NMR, C-13 NMR, IR, and HRMS, were used to characterize all synthesized compounds. The anti-tubercular activity of compounds 7a-p and 8a-k was assessed against Mtb H(37)Rv (ATCC 27294). These compounds demonstrated anti-tubercular activity against H37Rv in the range of 6.25-50 mu M. Swiss ADME's in silico computational studies showed that the ADME parameters were better and had a good pharmacokinetic profile. The compounds 8a, 7a, and 7p showed the most potential as anti-TB activity against Mtb H37Rv in this study, with MIC values of 6.25 mu M, 12.5 mu M, and 10 mu M, respectively. [Graphics]
引用
收藏
页码:1926 / 1937
页数:12
相关论文
共 26 条
[1]   Design, synthesis and 2D QSAR study of novel pyridine and quinolone hydrazone derivatives as potential antimicrobial and antitubercular agents [J].
Abdelrahman, Mohamed A. ;
Salama, Ismail ;
Gomaa, Mohamed S. ;
Elaasser, Mahmoud M. ;
Abdel-Aziz, Marwa M. ;
Soliman, Dalia H. .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2017, 138 :698-714
[2]   New class of antitubercular compounds: synthesis and anti-tubercular activity of 4-substituted pyrrolo[2,3-c]quinolines [J].
Akula, Mahesh ;
Sridevi, Jonnalagadda Padma ;
Yogeeswari, P. ;
Sriram, D. ;
Bhattacharya, Anupam .
MONATSHEFTE FUR CHEMIE, 2014, 145 (05) :811-819
[3]   Evolution of Drug-Resistant Mycobacterium tuberculosis Strains and Their Adaptation to the Human Lung Environment [J].
Allue-Guardia, Anna ;
Garcia, Juan I. ;
Torrelles, Jordi B. .
FRONTIERS IN MICROBIOLOGY, 2021, 12
[4]   A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis [J].
Andries, K ;
Verhasselt, P ;
Guillemont, J ;
Göhlmann, HWH ;
Neefs, JM ;
Winkler, H ;
Van Gestel, J ;
Timmerman, P ;
Zhu, M ;
Lee, E ;
Williams, P ;
de Chaffoy, D ;
Huitric, E ;
Hoffner, S ;
Cambau, E ;
Truffot-Pernot, C ;
Lounis, N ;
Jarlier, V .
SCIENCE, 2005, 307 (5707) :223-227
[5]  
Bendre AD., 2021, Current Res Pharmacol Drug Discov, V2, P100037, DOI [10.1016/j.crphar.2021.100037, DOI 10.1016/J.CRPHAR.2021.100037]
[6]  
Casal J.J., 2017, Austin Tuberc Res Treat, V2, P2
[7]   Mechanisms of resistance to delamanid, a drug for Mycobacterium tuberculosis [J].
Fujiwara, Mamoru ;
Kawasaki, Masanori ;
Hariguchi, Norimitsu ;
Liu, Yongge ;
Matsumoto, Makoto .
TUBERCULOSIS, 2018, 108 :186-194
[8]   In vitro antimycobacterial spectrum of a diarylquinoline ATP synthase inhibitor [J].
Huitric, Emma ;
Verhasselt, Peter ;
Andries, Koen ;
Hoffner, Sven E. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (11) :4202-4204
[9]   Identification of a novel class of quinoline-oxadiazole hybrids as anti-tuberculosis agents [J].
Jain, Puneet P. ;
Degani, Mariam S. ;
Raju, Archana ;
Anantram, Aarti ;
Seervi, Madhav ;
Sathaye, Sadhana ;
Ray, Muktikanta ;
Rajan, M. G. R. .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2016, 26 (02) :645-649
[10]   Quinoline: A promising antitubercular target [J].
Keri, Rangappa S. ;
Patil, Siddappa A. .
BIOMEDICINE & PHARMACOTHERAPY, 2014, 68 (08) :1161-1175